12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
If you are a sports fan, then you might consider the regulatory agenda of the U.S. Department of Lab...
Read More >
Organisations that appreciate how working parents have to balance their work and home responsibiliti...
Read More >
New Jersey has expanded its medical marijuana program and—for the first time since the state enacte...
Read More >
Our first update of 2020 outlines key UK employment law developments over the last month. It include...
Read More >
The Internal Revenue Service on September 23 finalized proposed regulations relating to hardship dis...
Read More >
Previously we introduced you to the FCPA and provided updates about the positive international trend...
Read More >